ipilimumab,nivolumab
bms
['nivo', 'nivolumab', 'ipi/', 'ipilimumab', 'renal,(-adrenal)', 'rcc,(-irccs),(-srcc),(-urcc)']
distinct outcomes in hispanic/latinx and non-hispanic/latinx patients with metastatic renal cell carcinoma (mrcc) treated with first-line ipilimumab plus nivolumab (ipi/nivo) #asco22 
#PsyOnc @CettroOncologia | Former Postdoc Fellow & Visiting Scholar @cityofhope | @IPOSPsychoOncol BOD 2021-2023 | #ASCO22 FCOI: https://t.co/wuOhYiJHBM